JGC
ALNY icon

J. Goldman & Co’s Alnylam Pharmaceuticals ALNY Stock Holding History

J. Goldman & Co’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.6M Buy
+38,698
New +$11.7M 0.3% 92
2026
Q1 		– Sell
-3,368
Closed -$1.15M – 652
2025
Q4 		$1.34M Buy
+3,368
New +$1.49M 0.04% 355
2025
Q2 		– Sell
-74,185
Closed -$20M – 452
2025
Q1 		$20M Buy
+74,185
New +$19.1M 0.49% 57

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

J. Goldman & Co's ALNY Position: Q2 2026 in Review

J. Goldman & Co opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 38,698 shares worth $11.6M. The stake represents 0.3% of the portfolio and ranks #92 among its holdings. This is a return to the name: J. Goldman & Co previously reported a position in ALNY as recently as Q4 2025.

J. Goldman & Co first reported a position in ALNY in Q1 2025 and has held it in 3 quarters since. The position peaked at $20M in Q1 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • J. Goldman & Co held 38,698 shares of Alnylam Pharmaceuticals worth $11.6M as of Q2 2026.
  • Alnylam Pharmaceuticals was a new J. Goldman & Co position in Q2 2026.
  • Alnylam Pharmaceuticals made up 0.3% of J. Goldman & Co's portfolio in Q2 2026, its #92 holding.
  • J. Goldman & Co first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • J. Goldman & Co's Alnylam Pharmaceuticals position peaked at $20M in Q1 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.